In ER+ breast cancer patients, adjuvant anti-estrogen treatment with aromatase inhibitors (AIs) and tamoxifen significantly reduced the risk of recurrence and death in all age groups studied2. The gene discussed is CYP19A1; the disease is breast cancer.